A reaction that runs smoothly in a 500 mL flask can behave very differently in a 500 L reactor.
Heat that dissipates quickly at lab scale can accumulate dangerously at plant scale. A reagent manageable in milligrams can become hazardous in kilograms.
Process safety in pharmaceutical scale-up catches these differences early. It is not a checkbox. It decides whether a route can be manufactured at all.
Why Scale Changes Everything
Lab flasks lose heat fast, since their surface area to volume ratio is high and excess heat escapes before building up.
Large reactors lack this advantage. As volume increases, surface area grows more slowly, leaving heat fewer ways out.
A reaction controlled at 100 g can become a thermal runaway risk at 50 kg. The chemistry has not changed, but the physics around it has. That is the core challenge of process safety pharmaceutical scale-up.
Understanding Exothermic Reactions: The MTSR Concept
Most API synthesis reactions are exothermic. The question is not how much heat they release, but what happens if cooling fails mid-reaction.
This is where MTSR, the Maximum Temperature of Synthesis Reaction, becomes critical: the highest temperature a mixture would reach if cooling stopped when unreacted material has accumulated.
The concept matters because:
• Reagents are often dosed in gradually rather than added all at once
• If the reaction is slower than the dosing rate, unreacted material builds up
• A cooling failure releases all accumulated heat at once
• MTSR shows the worst-case temperature
Teams compare MTSR to the Maximum Allowable Temperature (MAT), where decomposition begins. If MTSR exceeds MAT, the process carries thermal runaway risk that must be addressed before scale-up.
How Process Safety Teams Measure Reaction Hazards
Reaction calorimetry is the primary tool for characterizing exothermic behavior.
1. DSC: small-scale early screening that flags exothermic potential and decomposition onset
2. RC1: measures heat of reaction under process-like conditions, including dosing rate and stirring effects
3. ARC: used when DSC flags a concern, studying samples under adiabatic conditions for onset temperature and self-heating rate
Common practice: if the adiabatic temperature rise from screening exceeds roughly 50°C, teams move to RC1 for precise data before committing to scale.
Designing Around the Risk
Once a scale-up hazard assessment quantifies the risk, teams have several ways to make a route safer at scale.
• Dose control: slow addition so the reaction consumes reagent as fast as it arrives, preventing accumulation
• Temperature staging: run at a lower temperature where MTSR stays below MAT, even if cycle time grows
• Solvent selection: choose solvents with higher boiling points or better heat capacity
• Reactor design: jacketed reactors with higher cooling capacity, or semi-batch instead of batch
• Quench strategies: a fast-acting quench triggered if temperature limits are approached
The goal stays the same: keep MTSR below MAT under realistic failure scenarios, not just ideal conditions.
Managing Hazardous Intermediates
Exothermic risk is only part of the picture. Many API routes generate hazardous intermediates that need careful handling even when the reaction is thermally well-behaved.
• Genotoxic intermediates (GTIs): structurally reactive compounds that interact with DNA. ICH M7 sets strict daily exposure limits, often below 1.5 micrograms per day for the most potent categories
• Reactive organohalides: common in alkylation steps, needing controlled handling so they do not carry through to the final API
• Air or moisture-sensitive intermediates: need inert atmosphere handling, harder at larger scale
• Pyrophoric or unstable species: stable only within narrow temperature or concentration windows
Handling these needs containment matched to the hazard level: robust isolators, closed transfer systems, and dedicated cleaning protocols for higher-potency intermediates.
How LAXAI Approaches Process Safety in Scale-Up
LAXAI builds process safety into route selection and process development, not as an afterthought.
The team runs DSC and reaction calorimetry as standard practice for exothermic steps before finalizing scale-up decisions. MTSR is calculated against MAT for every critical reaction, with dose-controlled conditions designed wherever accumulation risk exists.
For routes generating hazardous intermediates, including genotoxic species, LAXAI’s analytical and process chemistry teams characterize the hazard and design containment matched to the exposure category.
LAXAI has specific expertise in high-energy chemistries and high-pressure reactions, areas most CDMOs decline. Process safety pharmaceutical scale-up assessments here cover a wider range of chemistries without defaulting to route avoidance.
Every process arrives at the plant with a documented hazard package, supporting GMP manufacturing safety standards and inspection readiness.
Talk to LAXAI’s process safety team at bd@laxai.com
FAQs
What is MTSR in pharmaceutical process safety?
MTSR is the highest temperature a mixture would reach if cooling failed at peak accumulation. It is compared against the Maximum Allowable Temperature to assess thermal runaway risk before scale-up.
Why does reaction safety change between lab and plant scale?
Larger reactors have a lower surface area to volume ratio, so heat escapes more slowly. A reaction that dissipates heat safely in a small flask can accumulate dangerous heat in a large reactor under the same conditions.
What calorimetry tools are used in process safety assessments?
DSC is used for early screening. RC1 measures heat of reaction under process-like conditions. ARC studies adiabatic behavior for reactions flagged as higher risk by DSC.
How are genotoxic intermediates managed during scale-up?
ICH M7 sets permitted daily exposure limits for genotoxic substances. Manufacturers use structure-based risk assessment, analytical controls, and containment matched to the exposure category.
